272 related articles for article (PubMed ID: 28161253)
41. Cloning, heterologous expression, and substrate specificities of protein farnesyltransferases from Trypanosoma cruzi and Leishmania major.
Buckner FS; Eastman RT; Nepomuceno-Silva JL; Speelmon EC; Myler PJ; Van Voorhis WC; Yokoyama K
Mol Biochem Parasitol; 2002 Jul; 122(2):181-8. PubMed ID: 12106872
[TBL] [Abstract][Full Text] [Related]
42. Pentamidine exerts in vitro and in vivo anti Trypanosoma cruzi activity and inhibits the polyamine transport in Trypanosoma cruzi.
Díaz MV; Miranda MR; Campos-Estrada C; Reigada C; Maya JD; Pereira CA; López-Muñoz R
Acta Trop; 2014 Jun; 134():1-9. PubMed ID: 24560964
[TBL] [Abstract][Full Text] [Related]
43. Carbonic anhydrase inhibitors: an editorial.
Supuran CT
Expert Opin Ther Pat; 2013; 23(6):677-9. PubMed ID: 23461558
[TBL] [Abstract][Full Text] [Related]
44. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents.
Werbovetz K
Curr Opin Investig Drugs; 2006 Feb; 7(2):147-57. PubMed ID: 16499285
[TBL] [Abstract][Full Text] [Related]
45. The in vivo and in vitro action of 4-amino-5-imidazolecarboxamide in trypanosomatid flagellates.
Kidder GW; Nolan LL
Mol Biochem Parasitol; 1981 Sep; 3(5):265-9. PubMed ID: 7029273
[TBL] [Abstract][Full Text] [Related]
46. Synthesis, structural elucidation and in vitro antiparasitic activity against Trypanosoma cruzi and Leishmania chagasi parasites of novel tetrahydro-1-benzazepine derivatives.
Gómez-Ayala S; Castrillón JA; Palma A; Leal SM; Escobar P; Bahsas A
Bioorg Med Chem; 2010 Jul; 18(13):4721-39. PubMed ID: 20627590
[TBL] [Abstract][Full Text] [Related]
47. Anti-leishmanial and anti-trypanosomal potential of polygodial isolated from stem barks of Drimys brasiliensis Miers (Winteraceae).
Corrêa DS; Tempone AG; Reimão JQ; Taniwaki NN; Romoff P; Fávero OA; Sartorelli P; Mecchi MC; Lago JH
Parasitol Res; 2011 Jul; 109(1):231-6. PubMed ID: 21243506
[TBL] [Abstract][Full Text] [Related]
48. Glycoconjugates isolated from Trypanosoma cruzi but not from Leishmania species membranes trigger nitric oxide synthesis as well as microbicidal activity in IFN-gamma-primed macrophages.
Camargo MM; Andrade AC; Almeida IC; Travassos LR; Gazzinelli RT
J Immunol; 1997 Dec; 159(12):6131-9. PubMed ID: 9550414
[TBL] [Abstract][Full Text] [Related]
49. Potential therapeutic use of herbal extracts in trypanosomiasis.
Teixeira TL; Teixeira SC; da Silva CV; de Souza MA
Pathog Glob Health; 2014 Jan; 108(1):30-6. PubMed ID: 24548158
[TBL] [Abstract][Full Text] [Related]
50. Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies.
Roldos V; Nakayama H; Rolón M; Montero-Torres A; Trucco F; Torres S; Vega C; Marrero-Ponce Y; Heguaburu V; Yaluff G; Gómez-Barrio A; Sanabria L; Ferreira ME; Rojas de Arias A; Pandolfi E
Eur J Med Chem; 2008 Sep; 43(9):1797-807. PubMed ID: 18192088
[TBL] [Abstract][Full Text] [Related]
51. Phytochemical and antiprotozoal activity of Ocotea lancifolia.
Fournet A; Ferreira ME; Rojas de Arias A; Guy I; Guinaudeau H; Heinzen H
Fitoterapia; 2007 Jul; 78(5):382-4. PubMed ID: 17499454
[TBL] [Abstract][Full Text] [Related]
52. Novel chemical starting points for drug discovery in leishmaniasis and Chagas disease.
Roquero I; Cantizani J; Cotillo I; Manzano MP; Kessler A; Martín JJ; McNamara CW
Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():58-68. PubMed ID: 31158574
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and biological evaluation of novel 2,3-disubstituted quinoxaline derivatives as antileishmanial and antitrypanosomal agents.
Cogo J; Kaplum V; Sangi DP; Ueda-Nakamura T; Corrêa AG; Nakamura CV
Eur J Med Chem; 2015 Jan; 90():107-23. PubMed ID: 25461316
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease.
Rodrigues GC; Feijó DF; Bozza MT; Pan P; Vullo D; Parkkila S; Supuran CT; Capasso C; Aguiar AP; Vermelho AB
J Med Chem; 2014 Jan; 57(2):298-308. PubMed ID: 24299463
[TBL] [Abstract][Full Text] [Related]
55. In vitro and experimental therapeutic studies of the calcium channel blocker bepridil: detection of viable Leishmania (L.) chagasi by real-time PCR.
Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
Exp Parasitol; 2011 Jun; 128(2):111-5. PubMed ID: 21354141
[TBL] [Abstract][Full Text] [Related]
56. High throughput screening for anti-Trypanosoma cruzi drug discovery.
Alonso-Padilla J; Rodríguez A
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3259. PubMed ID: 25474364
[TBL] [Abstract][Full Text] [Related]
57. Antioxidant defence system as a rational target for Chagas disease and Leishmaniasis chemotherapy.
Santi AMM; Murta SMF
Mem Inst Oswaldo Cruz; 2022; 117():e210401. PubMed ID: 35239945
[TBL] [Abstract][Full Text] [Related]
58. Parasitology. Drugs to combat tropical protozoan parasites.
Gelb MH; Hol WG
Science; 2002 Jul; 297(5580):343-4. PubMed ID: 12130767
[No Abstract] [Full Text] [Related]
59. Ultrastructural alterations and growth inhibition of Trypanosoma cruzi and Leishmania major induced by Bothrops jararaca venom.
Gonçalves AR; Soares MJ; de Souza W; DaMatta RA; Alves EW
Parasitol Res; 2002 Jul; 88(7):598-602. PubMed ID: 12107450
[TBL] [Abstract][Full Text] [Related]
60. In vitro screening of traditional South African malaria remedies against Trypanosoma brucei rhodesiense, Trypanosoma cruzi, Leishmania donovani, and Plasmodium falciparum.
Mokoka TA; Zimmermann S; Julianti T; Hata Y; Moodley N; Cal M; Adams M; Kaiser M; Brun R; Koorbanally N; Hamburger M
Planta Med; 2011 Sep; 77(14):1663-7. PubMed ID: 21412695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
